Scientists shed light on a sleep peptide involved in Alzheimer’s

An MCH axon in the brain of a mouse model of Alzheimer's disease

Leuven, 17 May 2023 - In the early stages of Alzheimer’s disease, people exhibit cognitive stability despite the presence of toxic proteins and neuronal hyperactivity in their brains. Researchers at the VIB-KU Leuven Center for Brain & Disease Research have uncovered early alterations in a brain region that controls neuron network activity and sleep. These findings open up exciting avenues for further research into the disease.

Most people are familiar with the devastating effects of Alzheimer's disease. However, many are not aware that the symptoms and underlying biology of Alzheimer's don't take place suddenly but instead progress over a long time.

One of the earliest stages of Alzheimer's is the prodromal phase. While the classic behavioral hallmarks of the disease may not be present during this stage, many people will experience other, more subtle differences, such as sleep disturbances. The prodromal phase is characterized by markers of the disease in the brain, such as a build-up of toxic proteins and neuron network hyperactivity.

Despite these physiological changes, cognition remains largely intact during the prodromal period of Alzheimer's disease, which strongly suggests the existence of homeostatic mechanisms that keep the brain functioning. These mechanisms are not yet well understood, although it is known that they are active during sleep and that they drive a net decrease in the strength and rate of neuron network excitation. Scientists have recently been studying the what, where, and how of this homeostatic system, the findings of which were published in Nature Neuroscience.

"Using a mouse model of Alzheimer's disease, we discovered that these homeostatic mechanisms are activated in the CA1 region, which is part of the hippocampus, a region of the brain important for learning and memory," Sara Calafate, one of the project leads, explains.
Joris de Wit, Sara Calafate, and Bart De Strooper

The interdisciplinary research team of neuroscientists, electrophysiologists, and pathologists – spanning labs and facilities across Belgium, Portugal, Israel, Switzerland, and the UK – found melanin-concentrating hormone (MCH) to be a key mechanism in the homeostatic system, harmonizing neuron network hyperactivity in the hippocampus.

"It was already known that neurons containing MCH reside in a small system of neurons located deep inside the brain called the lateral hypothalamic area. Despite its small size, this system is, in fact, a key player in the brain, with neurons that connect all the way to the CA1 region of the hippocampus." Joris de Wit, another co-lead based at the VIB-KU Leuven Center for Brain & Disease Research, highlights. "These MCH-expressing neurons are also known to be active during sleep and are involved in hippocampus-dependent memory. They're therefore a natural target of study for the prodromal phase of Alzheimer's. Indeed, we found that in both our Alzheimer's mouse model and in human brain tissue of Alzheimer patients, the connections of MCH neurons are damaged."

Promisingly, these scientists also found that by introducing an MCH peptide (a short string of amino acids, the building blocks of proteins) into hippocampal brain slices from an Alzheimer’s disease mouse model, they could reverse the hyperactivity in the hippocampal neuron network.

"All in all, our findings show the MCH system to be vulnerable in the early stages of Alzheimer's disease," Bart De Strooper – another study co-lead – shares. Bart De Strooper has been studying Alzheimer's at the VIB-KU Leuven Center for Brain & Disease research for over 30 years, in addition to acting as Scientific Director of the UK Dementia Research Institute. "In addition, the lateral hypothalamic area has not been previously demonstrated to be involved in the underlying neurobiology of Alzheimer's disease. This provides exciting avenues for research into the disease moving forward."

An MCH axon residing in the brain of a mouse model of Alzheimer's disease

Publication

Early alterations in the MCH system link aberrant neuronal activity and sleep disturbances in a mouse model of Alzheimer’s disease. Calafate, et al. Nature Neuroscience, 2023. https://doi.org/10.1038/s41593-023-01325-4


India Jane Wise

India Jane Wise

Science Communications Expert, VIB

About the VIB-KU Leuven Center for Brain & Disease Research

Scientists at the VIB-KU Leuven Center for Brain & Disease study how brain cells are organized and how they communicate with each other. These mechanisms reveal and provide insights into what goes wrong in brain diseases such as Alzheimer's, Parkinson's, ALS, and dystonia. This basic work should ultimately lead to new drugs for use against these currently incurable diseases.

Share

Latest stories

Website preview
Platform Enhances Purity and Reproducibility of Extracellular Vesicle Proteomics
Low-cost, high-throughput method improves purity and reproducibility of EV-based proteomics
press.vib.be
Website preview
Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline
Zwijnaarde, 1 July 2025 – Animab (“the Company”), a leader in pioneering first-in-class oral antibody solutions for unmet needs in production animals, announces the successful closing of a EUR 10 million Series B funding round. The investment will support the commercial launch of Animab Nanoprotec® as well as the advancement of its broader pipeline. This financing round follows shortly after Animab’s exclusive distribution agreement with Huvepharma1, reinforcing the strong momentum behind the upcoming commercialization of Nanoprotec® in the European market.
press.vib.be
Website preview
Researchers uncover surprising role of 'natural killer' cells in resistance to cancer immunotherapy
Targeting NK cells could open the door to more effective immunotherapy in resistant tumors
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be